Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
Stockholm, Sweden, November 6, 2023
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the publication of updated clinical data from the ongoing ALISON Phase 1 trial with the company’s lead program vididencel at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, the largest conference for cancer immunotherapy. The data demonstrate the boosting of broad immune responses in the majority of patients and a continued strong safety profile of vididencel.
Treatment of advanced ovarian cancer after surgery and chemotherapy remains challenging, due to high recurrence rates. The ALISON trial evaluates the use of vididencel as a maintenance treatment in ovarian cancer, aimed to prevent disease recurrence after first line treatment.
“While we are nearing completion of enrollment, the ALISON trial data presented at SITC 2023 demonstrate the potential of vididencel to boost a broad immune response, which is a prerequisite for controlling residual cancer cells and avoiding immune escape by tumor cells,” commented Jeroen Rovers, MD, PhD, Chief Medical Officer at Mendus. “We expect to fully enroll the ALISON trial before the end of 2023 and to report further clinical updates, including survival updates, in the first half of 2024.”
The data presented at SITC demonstrate that vididencel induces immune responses against tumor-associated antigens which are frequently upregulated in ovarian cancer. At the cut-off date for the SITC conference, 16 out of 17 patients had been enrolled in the ALISON study. T cell responses against a broad range of tumor-associated antigens present in vididencel were seen in 6 out of 8 evaluable patients. Immune responses against tumor-associated antigens, which are not present in vididencel were also observed following vididencel administration, suggesting broadening of the immune response due to so-called antigen spreading caused by tumor cell lysis. In addition to the observed T cell responses, B cell responses were improved, as demonstrated by the increased presence of memory B-cells and precursors of antibody-secreting B-cells in the majority of patients treated with vididencel.
The full abstract entitled “Induction of specific T-cell responses against tumor associated antigens and induction of B-cell responses in ovarian cancer patients by intradermal injection of vididencel” is available on the SITC conference website. The scientific poster presented at SITC 2023 is available via the Company’s website.
More information on the ALISON study is available on clinicaltrials.gov (trial ID: NCT04739527)
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting, CEO
ABOUT MENDUS AB (publ)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Vididencel is an off-the-shelf immunotherapy which is being developed as a cancer maintenance treatment, aimed at improving disease-free survival following first-line treatment. Vididencel is currently studied in a Phase 2 monotherapy trial in acute myeloid leukemia (AML) and a Phase 1 safety and feasibility trial in ovarian cancer. In December 2022, positive results from the ADVANCE II monotherapy Phase 2 trial in AML were presented at the American Society of Hematology (ASH) Annual Meeting. The analysis demonstrated the potential of vididencel to induce durable relapse-free survival in the majority of patients. Vididencel has received Orphan Drug Designation in Europe and the US and Fast Track Designation in the US for the treatment of AML. Mendus has secured a manufacturing alliance with NorthX Biologics for large-scale production of vididencel.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Notification of managers and closely related parties’ transactions with A.P. Møller - Mærsk A/S shares in connection with share buy-back program11.12.2023 10:28:17 CET | Press release
In connection with the announced share buy-back program in A.P. Møller - Mærsk A/S, A.P. Møller Holding A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Attachment APMM Share buy-back APMH sale 08122023
Indberetning af ledende medarbejderes og disses nærtståendes transaktioner med A.P. Møller - Mærsk A/S aktier i forbindelse med aktietilbagekøbsprogram11.12.2023 10:28:17 CET | pressemeddelelse
I forbindelse med det annoncerede aktietilbagekøbsprogram i A.P. Møller - Mærsk A/S sælger A.P. Møller Holding A/S løbende aktier pro rata og markedet informeres følgeligt herom - se vedhæftede fil. Vedhæftet fil APMM Aktietilbagekøbsprogram APMH salg_08122023
Aktietilbagekøb i Sydbank – transaktioner i uge 4911.12.2023 10:12:24 CET | pressemeddelelse
Selskabsmeddelelse nr. 43/2023 Peberlyk 4 DK-6200 Aabenraa Telefon +45 74 37 37 37 Telefax +45 74 37 35 36 Sydbank A/S CVR-nr. DK 12626509, Aabenraa sydbank.dk 11. december 2023 Aktietilbagekøb i Sydbank – transaktioner i uge 49 Sydbank offentliggjorde den 6. juli 2023 et aktietilbagekøbsprogram på 600 mio. kr. Aktietilbagekøbsprogrammet startede den 10. juli 2023 og vil være afsluttet senest den 31. januar 2024. Aktietilbagekøbsprogrammet sker med henblik på nedsættelse af aktiekapitalen i Sydbank og gennemføres efter bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 og EU Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016, samlet kaldet Safe Habour-reglerne. Under aktietilbagekøbsprogrammet er gennemført følgende transaktioner: Antal aktierGennemsnitlig købskursTransaktions-værdi (kr.)Akkumuleret seneste meddelelse 1.678.800 532.188.278,0004. december 2023 05. december 2023 06. december 2023 07. december 2023 08. december 2
Sydbank share buyback programme: transactions in week 4911.12.2023 10:12:24 CET | Press release
Company Announcement No 43/2023 Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 Fax +45 74 37 35 36 Sydbank A/S CVR No DK 12626509, Aabenraa sydbank.dk 11 December 2023 Dear Sirs Sydbank share buyback programme: transactions in week 49 On 6 July 2023 Sydbank announced a share buyback programme of DKK 600m. The share buyback programme commenced on 10 July 2023 and will be completed by 31 January 2024. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share buyback programme: Number of sharesVWAPGross value (DKK)Accumulated, most recent Announcement 1,678,800 532,188,278.0004 December 2023 05 December 2023 06 December 2023 0
Prepayments (CK93) - Totalkredit A/S11.12.2023 10:05:00 CET | Press release
To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 08 December 2023 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Totalkredit A/S Attachments Prepayments - Totalkredit A_S_11-12-2023eordindftk